Prosight Management’s Health Catalyst HCAT Stock Holding History

Prosight Management’s Portfolio HCAT Stock Details HCAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-347,724	Closed	-$3.7M	–	45
2022 Q4	$3.7M	Buy	+347,724	New	+$3.36M	2.02%	18

Other funds holding HCAT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Daventry Group New York $87.8M AUM 3.83% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Prosight Management's HCAT Position: Q1 2023 in Review

Prosight Management sold out of Health Catalyst (HCAT) in Q1 2023, closing a stake of 347,724 shares — an estimated $3.7M sold.

Prosight Management first reported a position in HCAT in Q4 2022 and held it in 1 quarter. The position peaked at $3.7M in Q4 2022. 162 funds tracked by Wall St. Rank hold HCAT as of Q1 2023.

Prosight Management reported no remaining Health Catalyst position as of Q1 2023 after selling out during the quarter.
Prosight Management sold 347,724 Health Catalyst shares in Q1 2023, an estimated $3.7M.
Prosight Management first reported a position in Health Catalyst in Q4 2022 and held it in 1 quarter.
Prosight Management's Health Catalyst position peaked at $3.7M in Q4 2022.
162 funds tracked by Wall St. Rank held Health Catalyst as of Q1 2023.

Based on Prosight Management's 13F filing for Q1 2023, filed 12 May 2023.